The cross-reactivity of human chorionic gonadotrophin (hCG) in the new DPC Immulite 2000 luteinizing hormone immunoassay was studied using sera from healthy pregnant women and pooled serum spiked with hCG standard IRP 75/537.
The cross-reactivity of human chorionic gonadotrophin (hCG) with competitive immunoassays for luteinizing hormone (LH) is well known. 1 LH and hCG are made up of two polypeptide subunits. The asubunit is common to both and the b-subunit of LH as hCG has sections with a high degree of homology. This means that assays for either hormone have to be designed to minimize cross-reactivity. In the new DPC Immulite 2000 assay for LH, we noticed clinically signi¢cant interference of hCG in the LH assay. We investigated this further using samples from pregnant women before and after the addition of the international standard for hCG (hCG IRP 75/537).
Serum pools A and B were prepared using serum samples from four healthy pregnant women. Dilutions of pools A and B were prepared using another serum pool with undetectable LH and hCG concentrations. This latter material was also used to prepare serial dilution of the hCG standard, IRP 75/537 (kindly supplied by the National Institute for Biological Standards and Control, South Mimms, UK). LH and hCG were measured using the DPC Immulite 2000 assays (Diagnostic Products Corporation, Glyn Rhonwy, Llanberis, Gwynedd, UK) according to the manufacturer's instructions. Figure 1 shows the e¡ect of increasing concentrations of hCG in the pregnancy pools and hCG standard, IRP 75/537, on measured LH concentrations. Figure 1 demonstrates that the Immulite 2000 LH assay detects more LH/LH-like epitopes in IRP 75/537 than in pregnancy samples, consistent with the presence of additional nicked hCG in IRP 75/537. 2 The percentage cross-reactivity of the IRP 75/537 hCG [calculated as (`measured LH/measured hCG)6100'] in the Immulite 2000 LH assay is shown in Table 1 . Although the percentage cross-reactivity decreases as the hCG concentration increases, the cross-reaction is still clinically signi¢cant as the concentration of hCG may be as high as 300 000 IU/L during the ¢rst trimester.
LH secretion is suppressed during pregnancy due to feedback inhibition by elevated gonadal steroids. However, in the pregnancy serum pools, LH concentration was measurable by the DPC Immulite 2000. This hCG-dependent positive bias, noticed in pregnancy samples, was con¢rmed with hCG IRP 75/537 at various dilutions. A recent report, using the current hCG standard, IRP 75/589, con¢rms our observations. 3 Women seeking medical advice for secondary amenorrhoea or menstrual irregularity could be pregnant. During investigation of these patients, misleading LH results could be obtained if there is signi¢cant cross-reactivity with hCG. Not all GPs measure serum hCG as the ¢rst-line test for secondary amenorrhoea, although some professional organizations suggest this as a guideline. 4 Therefore the knowledge of cross-reactivity of hCG with LH methods is important in interpreting gonadotrophin concentrations and for appropriate clinical advice. The modest degree of cross-reactivity shown in this study may cause diagnostic dilemma and may lead to delayed or inappropriate treatment. This is more important for laboratories using electronic auto-veri-¢cation of results.
This study emphasiz es the importance of the knowledge of cross-reactivity in interpreting immunoassay results. 
